Health ❯ Healthcare ❯ Clinical Trials ❯ Research Studies
The aldosterone‑synthesis inhibitor cut systolic readings by roughly 9–10 mmHg versus placebo in the BaxHTN trial, prompting plans for regulatory submissions.
